Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial
Diabetes Obesity and Metabolism2019Vol. 21(11), pp. 2465–2473
Citations Over TimeTop 11% of 2019 papers
Gilbert Ledesma, Guillermo E. Umpierrez, John E. Morley, Diane J. Lewis-D’Agostino, Annett Keller, Thomas Meinicke, Sandra van der Walt, Maximilian von Eynatten
Abstract
Addition of linagliptin improves glucose control without an excess of hypoglycaemia in older patients with type 2 diabetes on stable insulin therapy.
Related Papers
- → Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin(2015)22 cited
- → Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations(2016)26 cited
- → Linagliptin: A Novel Methylxanthin Based Approved Dipeptidyl Peptidase-4 Inhibitor(2012)14 cited
- → Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors(2017)11 cited
- → DPP-4 抑制劑 Linagliptin對抗β類澱粉蛋白導致神經毒性之保護作用(2014)